PERSONAL: After graduating from University College Cardiff with a BS in Biochemistry, Dr. Timothy Haystead completed a Ph.D. in Biochemistry at the University of Dundee. Dr. Haystead has extensive experience in all aspects of small molecule discovery and development.
Dr. Haystead is highly regarded in the field of academia, holding positions at Duke University as Professor of Cancer Biology and Pharmacology, Associate Professor of Pathology, and Member of the Duke Cancer Institute. His work has been recognized and funded by the National Institute of Health (NIH), Centers for Disease Control (CDC), US Department of Defense, the Cohen Foundation, and Bay Area Lyme Foundation. In the professional world, Dr. Haystead is the founder of biotechnology company Serenex, Inc. (Serenex), which discovered and developed the first orally bioavailable inhibitor of Hsp90, SNX5422. This compound has completed several Phase I and II clinical trials and is currently progressing through Phase III studies for cancer. Serenex was acquired by Pfizer in 2008. Furthermore, Dr. Haystead serves as the founder and president of Eyedisbio, which discovers and develops therapies for small molecules implicated in autoimmune and inflammatory diseases. Outside of the laboratory, Dr. Haystead’s interests include marine life, and tending to the lab saltwater aquarium, scuba diving, and surfing.